Truist raised the price target for the Adverum Biotechnologies Inc. (NASDAQ:ADVM) stock from “a Hold” to “a Buy”. The rating was released on July 07, 2022, according to finviz. The research report from SVB Leerink has downgraded the stock from Outperform to Mkt Perform, with a price target set at $5. The stock was downgraded by Truist, who disclosed in a research note on April 29, 2021, from Buy to Hold and set the price objective to $9. In their research brief published April 29, 2021, RBC Capital Mkts analysts downgraded the Adverum Biotechnologies Inc. stock from Outperform to Sector Perform with a price target of $6.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Adverum Biotechnologies Inc. (NASDAQ:ADVM) dipped -11.44% to close Friday’s market session at $0.75, lower as compared to yesterday’s close. The stock price fluctuated between $0.751 and $0.86 throughout the trading session with the volume trading being 811451 shares, which represented a significant variation when compared to the three months average volume of 476.16K shares. The firm’s stock price fluctuated -4.94% within the last five trades and 20.68% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -31.73% in the last 6 months and 18.96% was added to its value over the previous 3 months. ADVM stock is trading at a margin of 0.93%, 7.91% and -20.90% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
As of the close of trading, ADVM deals in the Healthcare domain. The stock is trading -58.74 percent below its 52-week high and 41.43 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -47.06. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Adverum Biotechnologies Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $76.81 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 0.36, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.20 percent of Adverum Biotechnologies Inc. shares are owned by insiders, and 64.50 percent are held by financial institutions. Fischer Laurent, the CEO, President and Director at Adverum Biotechnologies Inc. (ADVM) has sold 41,239 shares of firm on Mar 15 at a price of $0.78 against the total amount of $32232.0. In another inside trade, Soparkar Peter, Chief Operating Officer of Adverum Biotechnologies Inc. (NASDAQ:ADVM) sold 13,360 shares of the firm on Mar 15 for a total worth of $10442.0 at a price of $0.78. An inside trade which took place on Mar 15, Chief Scientific Officer of Adverum Biotechnologies Inc. Riley Brigit sold 7,299 shares of firm against total price of $5705.0 at the cost of $0.78 per share.